Summit Therapeutics Inc.
SMMTHealthcareNASDAQBiotechnology · Last scanned Sep 4, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of Sep 3CONFIRMED
Multi-indicator alignment: When 2+ indicators show the same condition on the same day, Scanance highlights it. This is not a recommendation. It means the technical indicators are aligned.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. At a $13.67B market cap, Summit Therapeutics Inc. ranks as a large-cap company within healthcare. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Market Cap
$13.67B
Beta
-1.24
P/E (TTM)
—
P/E (Fwd)
-14.37
EPS (TTM)
$-1.30
EPS (Fwd)
$-1.19
ROE
-192.5%
ROA
-101.6%
Cash
$690.7M
Total Debt
$20.4M
Free CF
-$139.7M
52W Change
-38.7%
Annual Financials
Cash vs Debt
Where SMMT stands vs its 150-day and 200-day moving averages
As of the August 31, 2026 close, SMMT finished 14.67% below its 150-day moving average ($16.09) and 16.69% below its 200-day moving average ($16.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SMMT overbought or oversold?
At the August 31, 2026 close, SMMT's RSI(14) was 41.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $690.7M in cash comfortably exceeding the $20.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$139.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -192.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $705K (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of -1.24 suggests SMMT is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SMMT.